Last reviewed · How we verify

Dextran 2-(Diethylamino)Ethyl Ether — Competitive Intelligence Brief

Dextran 2-(Diethylamino)Ethyl Ether (COLEXTRAN) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: colextran. Area: Metabolic.

phase 2 colextran Metabolic Live · refreshed every 30 min

Target snapshot

Dextran 2-(Diethylamino)Ethyl Ether (COLEXTRAN). Colextran works by binding to and removing excess cholesterol from the bloodstream.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Dextran 2-(Diethylamino)Ethyl Ether TARGET COLEXTRAN phase 2 colextran

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (colextran class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dextran 2-(Diethylamino)Ethyl Ether — Competitive Intelligence Brief. https://druglandscape.com/ci/colextran. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing